Table 2 Patient characteristics by tophi and frequency of gout flares
| Â | Number of self-reported tophi | Number of self-report flares in past 12 months | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No tophi (n =349) | Not sure (n = 195) | Any tophi (n = 76) | 0/don’t recall (n = 151) | 1 to 2 (n = 235) | 3 (n = 91) | 4 to 5 (n = 86) | 6+ (n = 57) | |||||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Male | 293 | 84% | 154 | 79% | 57 | 75.0% | 127 | 84% | 202 | 86% | 67 | 74% | 66 | 77% | 42 | 74% |
Age M (SD) | 61.6 | (11.2) | 61.1 | (11.6) | 57.0 | (12.6) | 62.0 | (11.2) | 61.3 | (11.2) | 59.9 | (12.9) | 59.1 | (11.9) | 60.5 | (11.1) |
Length of illness (years) M (SD) | 11.9 | (10.4) | 11.6 | (11.4) | 13.3 | (10.0) | 13.5 | (12.0) | 12.1 | (10.1) | 10.6 | (10.5) | 9.6 | (7.6) | 13.5 | (12.7) |
Employed | 140 | 40.1% | 69 | 35.4% | 30 | 39.5% | 54 | 35.8% | 94 | 40.0% | 38 | 41.8% | 29 | 33.7% | 24 | 42.1% |
Medication | ||||||||||||||||
  Allopurinol | 182 | 52.1% | 94 | 48.2% | 43 | 56.6% | 91 | 60.3% | 104 | 44.3% | 46 | 50.5% | 48 | 55.8% | 30 | 52.6% |
  Febuxostat | 8 | 2.3% | 5 | 2.6% | 16 | 21.1% | 4 | 2.6% | 11 | 4.7% | 5 | 5.5% | 4 | 4.7% | 5 | 8.8% |
  Probenecid | 8 | 2.3% | 4 | 2.1% | 6 | 7.9% | 6 | 4% | 6 | 2.6% | 2 | 2.2% | 2 | 2.3% | 2 | 3.5% |
  Benzbromarone | 0 | 0% | 0 | 0% | 4 | 5.3% | 0 | 0% | 1 | 0.4% | 1 | 1.1% | 2 | 2.3% | 0 | 0% |
  Other | 45 | 12.9% | 40 | 20.5% | 12 | 15.8% | 5 | 3.3% | 32 | 13.6% | 74 | 18.7% | 26 | 30.2% | 17 | 29.8% |
  none | 120 | 34.4 | 63 | 32.3 | 11 | 14.5% | 48 | 31.8% | 90 | 38.3% | 27 | 29.7% | 17 | 19.8% | 12 | 21.1% |
  sUA | ||||||||||||||||
  Unknown | 253 | 72.5% | 152 | 77.9% | 43 | 56.6% | 116 | 76.8% | 168 | 71.5% | 65 | 71.4% | 57 | 66.3% | 42 | 73.7% |
  <6 mg/d | 45 | 12.9% | 13 | 6.7% | 4 | 5.3% | 23 | 15.2% | 28 | 11.9% | 4 | 4.4% | 5 | 5.8% | 2 | 3.5% |
  6-8 mg/dL | 40 | 11.5% | 19 | 9.7% | 16 | 21.1% | 6 | 4% | 30 | 12.8% | 18 | 19.8% | 15 | 17.4% | 6 | 10.5% |
  >8 mg/dL | 11 | 3.2% | 11 | 5.6% | 13 | 17.1% | 6 | 4% | 9 | 3.8% | 4 | 4.4% | 9 | 10.5% | 7 | 12.3% |
Tophi | ||||||||||||||||
  No tophi | - | - | - | - | - | - | 109 | 72.2% | 142 | 60.4% | 44 | 48.4% | 33 | 38.4% | 21 | 36.8% |
  Not sure | - | - | - | - | - | - | 38 | 25.2% | 65 | 27.7% | 33 | 36.3% | 34 | 39.5% | 25 | 43.9% |
  Any tophi | - | - | - | - | - | - | 4 | 2.6% | 28 | 11.9% | 14 | 15.4% | 19 | 22.1% | 11 | 19.3% |
Flares | ||||||||||||||||
  0/don’t recall | 109 | 31.2% | 38 | 19.5% | 4 | 5.3% | - | - | - | - | - | - | - | - | - | - |
  1 to 2 | 142 | 40.7% | 65 | 33.3% | 28 | 36.8% | - | - | - | - | - | - | - | - | - | - |
  3 | 44 | 12.6% | 33 | 16.9% | 14 | 18.4% | - | - | - | - | - | - | - | - | - | - |
  4 to 5 | 33 | 9.5% | 34 | 17.4% | 19 | 25.0% | - | - | - | - | - | - | - | - | - | - |
  6+ | 21 | 6.0% | 25 | 12.8% | 11 | 14.5% | - | - | - | - | - | - | - | - | - | - |